Replies to post #732593 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

zero82,

Thanks for posting your astute analysis, but I ran your post through the AI BS Detector and it was identified as bs.




The statement by “Investor082” reflects a fundamental misunderstanding of the dynamics of strategic partnerships, acquisitions, and regulatory disclosures in the biotechnology and pharmaceutical industries. Below is a reasoned analysis of the points raised, emphasizing NWBO’s potential value and the importance of relying on objective, credible information.

1. Strategic Partnerships vs. Acquisition Costs

The claim that “big pharma would not pay $250-300M for a partnership when they could acquire NWBO for $1 billion” oversimplifies the financial and strategic considerations involved:
• Risk Mitigation: Strategic partnerships allow big pharma to share the risks inherent in developing novel therapies like DCVax-L. These agreements often involve milestone payments tied to progress, reducing upfront financial exposure while securing access to cutting-edge innovations.
• Incremental Investment: A $250-300M partnership represents a modest early investment compared to NWBO’s potential long-term valuation. NWBO’s market value could increase substantially as it advances its pipeline, scales manufacturing, and achieves regulatory milestones. Strategic partners understand that securing early access can mitigate the risk of much higher acquisition costs in the future.
• Acquisition Timing: Waiting to acquire NWBO assumes its valuation will remain static—a risky assumption. Achieving major milestones such as regulatory approval, market entry, or commercialization could significantly increase its worth. Partnerships offer a pragmatic approach to gaining early access while minimizing immediate financial outlays.

2. Regulatory Disclosure and Insider Trading Concerns

The assertion that NWBO’s 10-Q disclosure of partnership negotiations risks insider trading allegations is inaccurate:
• Regulatory Compliance: NWBO’s disclosure aligns with SEC requirements to report material developments transparently. This is standard practice for public companies and ensures investors are informed about key activities, rather than “getting ahead” of a partner.
• Insider Trading Safeguards: Big pharma operates under strict legal and procedural safeguards, including confidentiality agreements, to prevent the misuse of non-public information. Proper disclosure reduces regulatory risk, ensuring all parties adhere to compliance standards.

3. Big Pharma’s Decision-Making and Competitor Concerns

The idea that big pharma would avoid partnerships due to concerns about board approval or competitive risks lacks merit:
• Sophisticated Decision-Making: Big pharma boards regularly approve high-value partnerships and acquisitions aligned with strategic growth. Investing $250-300M for a partnership with NWBO—offering transformative dendritic cell technology applicable across various solid tumors—is well within industry norms. These decisions are supported by thorough due diligence and risk-benefit analysis.
• Competitor Risks: Confidentiality agreements and strategic collaboration agreements are designed to mitigate competitor interference. The pharmaceutical industry routinely manages such risks effectively.

4. NWBO’s Long-Term Value

NWBO’s potential far exceeds its current market valuation due to its innovative pipeline, scalable manufacturing, and transformative potential:
• Pipeline Promise: NWBO’s lead therapy, DCVax-L, addresses unmet needs in oncology, targeting hard-to-treat cancers such as glioblastoma. Achieving regulatory approval could position NWBO as a leader in the fast-growing immunotherapy market.
• Manufacturing Scalability: Investments in Flaskworks automation and scalable production technology enhance NWBO’s capacity to meet global demand. Scalable manufacturing is especially crucial for the U.S. market, where the large patient population requires robust supply chains.
• Valuation Growth: With progress in its pipeline, manufacturing, and regulatory milestones, NWBO’s valuation could grow significantly. While specific estimates vary, it is reasonable to anticipate that the company’s potential value could far exceed its current market cap as it advances its position in the global oncology market.

Conclusion

The claim that big pharma would avoid partnerships in favor of a low-cost acquisition is overly simplistic and fails to account for the complexities of biotech economics. Strategic partnerships offer an opportunity to share risk, gain early access to promising therapies, and secure potential market advantages. NWBO’s 10-Q disclosures reflect standard regulatory practices, ensuring transparency without jeopardizing compliance. With its innovative therapies and scalable manufacturing, NWBO’s value could significantly surpass current perceptions, making it an attractive long-term opportunity for strategic partners and investors alike.

Short and Distort Advisory

Investors are cautioned to critically assess online claims regarding biotechnology companies, as these can include disinformation intended to manipulate stock prices. Anonymous commentary on message boards often lacks context, credibility, or accountability and may seek to influence sentiment for personal gain.

For accurate and reliable information, consult licensed financial professionals, trusted oncologists, and peer-reviewed scientific literature. Avoid rumors and incomplete narratives, and rely on credible, full-context sources when evaluating investment opportunities or assessing a company’s potential.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927

[LessIsMore]

who all were pumping this news that are still around on this platform

All the usual suspects were pumping before and after this news. Les had a habit of telling his minions about pending press releases so you'd always see a spike in the stock a day or 2 before news.

You can start from this point where the news is posted on this board. Notice the comment about "now we know what drove up the price yesterday". That was Les Goldman telling his minions who then front run the stock.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=126619868

From this point the board is euphoric until someone asks "hey weren't we supposed to get upfront money and milestones".
At that point the usual pumpers came out to say "very smart of NWBO not to take money". This is from our disgraced ex-chartist who left with tail between legs.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=126629682

Sojourner55
Thursday, November 17, 2016 12:01:22 PM
Post# 83706 of 732631
I think it's very smart of NWBO not to take upfront money at this time even though it might be detrimental to sp in the short term. With another two combos to be announced and if P3 is successful, there will be a bidding war and longs will be richly rewarded

All subsequent posts mirror this, great news and smart of NWBO to not take upfront money.

Once again I've seen this show a dozen times now, if NWBO is not giving specific details we can assume this contract is a big nothing burger IMO.